If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many cancers, can vary from cancer to cancer and even patient to patient, a discovery that adds to a growing base of knowledge important for developing more effective precision therapies.
Findings from the study, led by Han Liang, Ph.D., associate professor of Bioinformatics and Computational Biology, and Gordon Mills, M.D., Ph.D., chair of Systems Biology, were published in the April 26 online issue of Cancer Cell.
Liang’s and Mills’ team discovered how a particular type of RNA editing called adenosine to inosine (A-to-I) RNA plays a key role in protein variation in cancer cells. RNA editing is the process by which genetic information is altered in the RNA molecule. Once thought rare in humans and other vertebrates, RNA editing is now recognized as widespread in the human genome.
Since cancer can arise from vastly different protein types and mutations, the promise of individualizing therapies for each patient is reliant upon a better understanding of the protein “genome,” an area of study called proteomics. Understanding the molecular mechanism contributing to protein variation and diversity is a key question in cancer research today, with significant clinical applications for cancer treatment.
“Using data from The Cancer Genome Atlas and the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium, our study provides large-scale direct evidence that A-to-I RNA editing is a source of proteomic diversity in cancer cells,” said Liang. “RNA editing represents a new paradigm for understanding the molecular basis of cancer and developing strategies for precision cancer medicine. If a protein is only highly edited in tumor proteins, but not in normal proteins, then it’s possible that a specific drug could be designed to inhibit the edited mutant protein.”
It has long been known that A-to-I RNA editing allows cells to tweak the RNA molecule resulting in nucleotide sequences which alter DNA “instructions” for how proteins are generated and how they are assembled within the cell.
The researchers demonstrated how A-to-I RNA editing contributes to protein diversity in breast cancer by making changes in amino acid sequences. They found one protein, known as coatomer subunit alpha (COPA), increased cancer cell proliferation, migration and invasion in vitro, following A-to-I RNA editing.
“Collectively, our study suggests that A-to-I RNA editing contributes to protein diversity at least in some cancers,” said Mills. “It is an area of study that deserves more effort from the cancer research community to elucidate the molecular basis of cancers, and potentially developing prognostic and therapeutic approaches.”
Receive an email update when we add a new PRECISION MEDICINE article.
The Latest on: Precision cancer medicine
via Google News
The Latest on: Precision cancer medicine
- Davis-based cancer drug startup aims to raise $2.7 million on December 16, 2018 at 11:07 am
New momentum has struck Ariz Precision Medicine, a Davis-based startup that’s researching a potential cure for cancer. Ariz said it has $2 million committed in recent months between investments from t... […]
- Precision Medicine in Differentiated Thyroid Cancer on December 14, 2018 at 7:41 am
Eric J. Sherman, MD: The nice thing about thyroid cancer, especially papillary thyroid cancer, is that targetable mutations exist. Right now, everyone knows about BRAF. It’s the most common mutation, ... […]
- Genomic Sequencing: precision data to better fight advanced cancer on December 7, 2018 at 6:35 pm
That precision data led Olson to a clinical ... Five months in to that treatment, his tests show no active cancer in his blood. And he’s now five years removed from a diagnosis that initially ... […]
- He Saved the Largest Venomous Snake in the Americas. Now, He Hopes It Could Save Human Lives. on December 6, 2018 at 10:34 am
With the quickness and precision ... that kill cancer cells, if you put them with normal cells they’ll kill them very nicely as well.” Clinical testing for venom-derived drugs only started ... […]
- CSI Laboratories Advances Precision in Cancer Diagnostics by Partnering with Dr. Maher Albitar of Genomics Testing Cooperative (GTC) on December 5, 2018 at 6:29 am
M.D.,to discuss the partnership’s goals and forthcoming capabilities regarding cancer diagnostics. MOLECULAR PATHOLOGY WEBINAR Next Generation Sequencing in the practice of Precision Medicine January ... […]
- Cancer-fighting device blasts tumors with power and precision on December 3, 2018 at 9:55 pm
A new form of advanced radiation therapy for cancer patients being used at Mercy ... high dose of radiation delivered with accuracy and precision. It goes where it needs to go and does so each treatme... […]
- Systems Epigenetics: Towards Precision Cancer Medicine on November 30, 2018 at 3:38 pm
This conference brings together scientists from multidisciplinary fields employing different research strategies: Epigenetic profiling at genome-wide and/or single cell level to identify complex dynam... […]
- Precision Medicine Market Size and Key Trends in terms of Volume and Value 2018 - 2025 on November 27, 2018 at 12:01 am
The precision medicine market is anticipated to grow with a significant rate in the coming years, owing to factors such as, growing prevalence of cancer, rising adoption of gene therapy to reduce cost ... […]
- Precision Medicine Has Transformed Cancer Treatment. Here’s How to Move It Beyond Oncology on November 12, 2018 at 2:22 pm
The 21st century is the century of biology, where we’re seeing tremendous discoveries in science and medicine that are improving quality of life for people around the world. We are already seeing proo... […]
via Bing News